Design Therapeutics VP Finance Resigns; Controller Appointed Interim Principal Accounting Officer

Design Therapeutics, Inc.

Justin Thacker resigned as VP Finance and principal accounting officer effective August 13, 2021.
Dawn Giangiulio, Controller since April 2020, appointed interim principal accounting officer effective August 13, 2021.
Giangiulio also serves as Controller of ARS Pharmaceuticals on a part-time basis, resigning September 3, 2021.
Previously, Giangiulio was Senior Manager R&D Finance at Teva Pharmaceutical Industries from 2015 to 2020.
Giangiulio is a licensed CPA and began her career at PricewaterhouseCoopers.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Justin Thacker

VP, Finance

DSGN · Design Therapeutics, Inc.

Effective: 2021-08-13
Successor: Dawn Giangiulio
Filed: August 6, 2021, 7:59 PM ET

On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. (the “Company”) of his intention to resign as the Company’s VP, Finance and from his position as the Company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity.

Appointed (interim)

Dawn Giangiulio

interim principal accounting officer

DSGN · Design Therapeutics, Inc.

Effective: 2021-08-13
Filed: August 6, 2021, 7:59 PM ET

Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Justin Thacker resigned as VP, Finance at Design Therapeutics, Inc..

Action: resigned
Role: VP, Finance

Exact text from the filing

On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. (the “Company”) of his intention to resign as the Company’s VP, Finance and from his position as the Company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dawn Giangiulio was appointed as interim principal accounting officer at Design Therapeutics, Inc..

Action: appointed
Role: interim principal accounting officer

Exact text from the filing

Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended.

View on SEC.gov

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-239304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.